Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
|
|
- Michael Henry
- 5 years ago
- Views:
Transcription
1 Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December 31, 20xx Measure Steward Endrsed by Descriptin Measure scring Measure type Ratinale Clinical Recmmendatin Statement References American Medical Assciatin Physician Cnsrtium fr Perfrmance Imprvement Natinal Quality Frum Percentage f patients aged 18 years and lder with a diagnsis f heart failure and LVSD (LVEF < 40%) wh were prescribed ACE inhibitr r ARB therapy. Prprtin Prcess In the absence f cntraindicatins, ACE Inhibitrs r ARBs are recmmended fr all patients with symptms f heart failure and reduced left ventricular systlic functin, as measured by left ventricular ejectin fractin (LVEF). Bth drugs have been shwn t decrease mrtality and hspitalizatins. Heart Failure: Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD). Angitensin cnverting enzyme inhibitrs are recmmended fr all patients with current r prir symptms f HF and reduced LVEF, unless cntraindicated. (Class I Recmmendatin, Level f Evidence: A)(ACC/AHA) Angitensin II receptr blckers apprved fr the treatment f HF are recmmended in patients with current r prir symptms f HF and reduced LVEF wh are ACEI intlerant. (Class I Recmmendatin, Level f Evidence: A) (ACC/AHA) Angitensin II receptr blckers are reasnable t use as alternatives t ACEIs as first line therapy fr patients with mild t mderate HF and reduced LVEF, especially fr patients already taking ARBs fr ther indicatins (Class IIa Recmmendatin, Level f Evidence: A) (ACC/AHA). Definitins
2 Table f Cntents Ppulatin criteria Data criteria (QDS Data Elements) Summary calculatin Please refer t the spreadsheet fr this measure fr detail regarding data criteria and cde lists. Ppulatin criteria Initial Patient Ppulatin = Denminatr = Numeratr = Exclusins = Patient characteristic: birth date (age) >=18 years; Diagnsis active: heart failure ; OR: >=2 cunt(s) f: OR: Encunter: encunter utpatient ; OR: Encunter: encunter nursing facility ; OR: >=1 cunt(s) f: Encunter: encunter inpatient discharge ; All patients in the initial patient ppulatin; OR: Diagnstic study result: LVF assessment, result <40%; OR: Diagnstic study result: ejectin fractin, result <40%; OR: Medicatin rder: ACE inhibitr r ARB ; OR: Medicatin active: ACE inhibitr r ARB ; OR: Medicatin allergy: ACE inhibitr r ARB ; OR: Medicatin adverse event: ACE inhibitr r ARB ; OR: Medicatin intlerance: ACE inhibitr r ARB ; OR: Diagnsis active: pregnancy ; OR: Diagnsis active: deficiencies f circulating enzymes ; OR: Diagnsis active: disease f artic and mitral valves ; OR: Diagnsis active: nn rheumatic mitral (valve) disease ; OR: Diagnsis active: chrnic kidney disease with r withut hypertensin ; OR: Diagnsis active: hypertensive renal disease with renal failure ; OR: Diagnsis active: athersclersis f renal artery ; OR: Diagnsis active: renal failure and ESRD ; OR: Diagnsis active: acute renal failure ; OR: Diagnsis active: atresia and stensis f arta ; OR: Medicatin nt dne: medical reasn ; OR: Medicatin nt dne: patient reasn fr ACE inhibitr r ARB decline ;
3 OR: Medicatin nt dne: patient reasn ; OR: Medicatin nt dne: system reasn ; Data Criteria (QDS Data Elements) Initial Patient Ppulatin = Denminatr = Numeratr = Exclusins = "Patient characteristic: birth date using birth date cde list befre the measurement perid ; Diagnsis active: heart failure using heart failure cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Encunter: encunter utpatient using encunter utpatient cde list during the measurement perid ; Encunter: encunter nursing facility using encunter nursing facility cde list during the measurement perid ; Encunter: encunter inpatient discharge using encunter inpatient discharge cde list during the measurement perid ; All patients in the initial patient ppulatin; Diagnstic study result: LVF assessment using LVF assessment cde list befre Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnstic study result: ejectin fractin using ejectin fractin cde list befre Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin rder: ACE inhibitr r ARB using ACE inhibitr r ARB cde list during the measurement perid ; Medicatin active: ACE inhibitr r ARB using ACE inhibitr r ARB cde list during the measurement perid ; Medicatin allergy: ACE inhibitr r ARB using ACE Inhibitr r ARB cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin adverse event: ACE inhibitr r ARB using ACE Inhibitr r ARB cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin intlerance: ACE inhibitr r ARB using ACE Inhibitr r ARB cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: pregnancy using pregnancy cde list gruping during Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: deficiencies f circulating enzymes using deficiencies f circulating enzymes cde list gruping befre r simultaneusly t Encunter: encunter
4 utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: disease f artic and mitral valves using disease f artic and mitral valves cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: nn rheumatic mitral (valve) disease using nnrheumatic mitral (valve) disease cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: chrnic kidney disease with and withut hypertensin using chrnic kidney disease with and withut hypertensin cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: hypertensive renal disease with renal failure using hypertensive renal disease with renal failure cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: athersclersis f renal artery using athersclersis f renal artery cde list cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: renal failure and ESRD using renal failure and ESRD cde list befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Diagnsis active: acute renal failure using acute renal failure cde list befre r simultaneusly t Encunter: utpatient OR Encunter: nursing facility OR Encunter: inpatient discharge ; Diagnsis active: atresia and stensis f arta using atresia and stensis f arta cde list gruping befre r simultaneusly t Encunter: encunter utpatient OR Encunter: encunter nursing facility OR Encunter: encunter inpatient discharge ; Medicatin nt dne: medical reasn using medical reasn cde list fr Medicatin rder: ACE inhibitr r ARB OR Medicatin active: ACE inhibitr r ARB ; Medicatin nt dne: patient reasn fr ACE inhibitr r ARB decline using patient reasn fr ACE inhibitr r ARB decline cde list fr Medicatin rder: ACE inhibitr r ARB OR Medicatin active: ACE inhibitr r ARB ; Medicatin nt dne: patient reasn using patient reasn cde list fr Medicatin rder: ACE inhibitr r ARB OR Medicatin active: ACE inhibitr r ARB ; Medicatin nt dne: system reasn using system reasn cde list fr Medicatin rder: ACE inhibitr r ARB OR Medicatin active: anti platelet therapy ; Summary Calculatin Calculatin is generic t all measures: Calculate the final denminatr by adding all that meet denminatr criteria. Subtract frm the final denminatr all that d nt meet numeratr criteria yet als meet exclusin criteria. Nte sme measures d nt have exclusin criteria. The perfrmance calculatin is the number meeting numeratr criteria divided by the final denminatr.
5 Fr measures with multiple patient ppulatins, repeat this prcess fr each patient ppulatin and reprt each result separately. Fr measures with multiple numeratrs, calculate each numeratr separately within each ppulatin using the paired exclusin. Measure set CLINICAL QUALITY MEASURE SET
Heart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure
More informationCoronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)
Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD
More informationDiabetes: HbA1c Poor Control (NQF 0059)
Diabetes: HbA1c Pr Cntrl (NQF 0059) EMeasure Name Diabetes: HbA1c Pr Cntrl EMeasure Id Pending Versin Number 1 Set Id Pending Available Date N infrmatin Measurement January 1, 20xx thrugh Perid December
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationMeasure Information Form
Release Ntes: Measure Infrmatin Frm Versin 2.0 **NQF-ENDORSED VOLUNTRY CONSENSUS STNDRDS FOR HOSPITL CRE** Measure Set: Heart Failure (HF) Set Measure ID#: Measure Infrmatin Frm Perfrmance Measure Name:
More informationWeight Assessment and Counseling for Children and Adolescents (NQF 0024)
Weight Assessment and Cunseling fr Children and Adlescents (NQF 0024) EMeasure Name Weight Assessment and EMeasure Id Pending Cunseling fr Children and Adlescents Versin Number 1 Set Id Pending Available
More informationHigh Performance Network Quality Criteria for Designation
Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More information2018 CMS Web Interface
CMS Web Interface HTN-2 (NQF 0018): Cntrlling High Bld Pressure Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 18 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE SAMPLING INFORMATION... 4
More information2018 CMS Web Interface
CMS Web Interface IVD-2 (NQF 0068): Ischemic Vascular Disease (IVD): Use f Aspirin r Anther Measure Steward: NCQA CMS Web Interface V2.0 Page 1 f 20 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationSignificance of Chronic Kidney Disease in 2015
1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More information2018 CMS Web Interface
CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE
More information2018 CMS Web Interface
PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS
More information2018 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 23 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationEchocardiography Diagnostic Accuracy
Echcardigraphy Diagnstic Accuracy Measure Descriptin: The prprtin f ptentially preventable and clinically imprtant inaccurate diagnses amng cngenital heart surgical patients. Numeratr Number f cngenital
More informationUse of sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Shared Care Protocol
Oxfrdshire Clinical Cmmissining Grup Use f sacubitril valsartan fr the treatment f symptmatic chrnic heart failure with reduced ejectin fractin. Shared Care Prtcl This prtcl prvides prescribing and mnitring
More information2017 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Fllw-Up Measure Steward: CMS Web Interface V1.0 Page 1 f 22 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More information2017 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF 0055): Diabetes: Eye Exam Measure Steward: NCQA Web Interface
More information2017 CMS Web Interface
CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS Web Interface V1.1 Page 1 f 27 12/15/2016 Cntents INTRODUCTION... 4 WEB INTERFACE SAMPLING
More informationBP Thresholds for Medical Review
BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More informationMichigan Primary Care Transformation Project Performance Incentive Technical Manual
Michigan Primary Care Transfrmatin Prject 2016 Perfrmance Incentive Technical Manual Fr Physician Organizatins, Physician Hspital Organizatins, Independent Practice Assciatins and Primary Care Practices
More information2018 CMS Web Interface
CMS Web Interface Diabetes Mellitus (DM) Cmpsite (All r Nthing Scring) DM-2 (NQF 0059): Diabetes: Hemglbin A1c (HbA1c) Pr Cntrl (>9%) DM-7 (NQF Measure Steward: NCQA CMS Web Interface V2.1 Page 1 f 26
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationClinical Study Synopsis
Clinical Study Synpsis This Clinical Study Synpsis is prvided fr patients and healthcare prfessinals t increase the transparency f Bayer's clinical research. This dcument is nt intended t replace the advice
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More information2017 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening and Fllw- Measure Steward: CMS Web Interface V1.0 Page 1 f 23 11/15/2016 Cntents INTRODUCTION... 3 WEB
More informationNQF 0075 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
NQF 0075 Ischemic Vascular Disease (IVD): Cmplete Lipid Panel and LDL Cntrl Initial Patient Ppulatin: Numeratr(1): Numeratr(2): N Exclusin: Denminatr: D Exceptin: D Exclusin: Patients 18 years f age and
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationLTCH QUALITY REPORTING PROGRAM
4 LTCH QUALITY REPORTING PROGRAM GENERAL INFORMATION...3 LTCH FACILITY-LEVEL QUALITY MEASURE REPORT...5 LTCH PATIENT-LEVEL QUALITY MEASURE REPORT...18 LTCH REVIEW AND CORRECT REPORT...23 09/2018 v1.04
More informationNational Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes
Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.6 Cmpleted: Nvember 28, 2018 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins
More information2018 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 24 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationNPCR CLINICAL EDIT CHECKS
NPCR CLINICAL EDIT CHECKS FCDS Annual Meeting July 26, 2013 Sunrise, Flrida Steven Peace, CTR FCDS Data Quality Staff PURPOSE OF CLINICAL EDIT CHECKS The primary purpse f the Clinical Check edits is t
More informationo Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17
Request fr Prir Authrizatin Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 All requests fr Pulmnary Arterial
More informationICD-10-CM Coding Basics Chapter Specifics
ICD-10-CM Cding Basics Chapter Specifics Chapter 15 Pregnancy, Childbirth and the Puerperium Vilma Smith, LVN, CPC, CCS Debra Bales, LVN, CPC Jnay Rischer, CPC 1 Rev. May 2015 ICD-10-CM Cnventins General
More informationCOPD Outreach Program
COPD Outreach Prgram Wendy Laframbise, Advanced Practice Nurse Certified Respiratry Educatr COPD Outreach Prgram March, 2015 Disclaimer: The Canadian Fundatin fr Healthcare Imprvement (CFHI), in partnership
More informationMeasure Specific Guidelines for Comprehensive Diabetes Care (CDC)
Measure Specific Guidelines fr Cmprehensive Diabetes Care (CDC) Descriptin: Members age 18-75 years f age with diabetes (Type 1 and Type 2)* that had all f the fllwing: *Members in hspice are excluded
More information2018 CMS Web Interface
CMS Web Interface PREV-9 (NQF 0421): Preventive Care and Screening: Bdy Mass Index (BMI) Screening Measure Steward: CMS CMS Web Interface V2.0 Page 1 f 23 11/13/2017 Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationCognitive enhancers for the treatment of Alzheimer s disease
Cmprehensive Research Plan: Cgnitive enhancers fr the treatment f Alzheimer s disease Pharmacepidemilgy Unit February 13 th, 2015 30 Bnd Street, Trnt ON, M5B 1W8 www.dprn.ca inf@dprn.ca 2 ODPRN Drug Class
More informationTrust Guideline for Urgent Brain Imaging and Management of Suspected Subarachnoid Haemorrhage
A Clinical Guideline Fr Use in: Accident & Emergency, Acute Medical Unit, Medical wards By: Medical staff Fr: Adult patients presenting with suspected subarachnid haemrrhage Divisin respnsible fr dcument:
More informationTechnical Specifications of Pediatric Ambulatory Care Sensitive Condition Hospitalizations
Technical Specificatins f Pediatric Ambulatry Care Sensitive Cnditin Hspitalizatins Surce: The Canadian Institute fr Health Infrmatin Database(s): Discharge Abstract Database (DAD) Level(s) f Care (facility
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More information2013 DATA COLLECTION GUIDE Summary Data Submission. Optimal Asthma Care. (07/01/2012 to 06/30/2013 Dates of Service)
2013 DATA COLLECTION GUIDE Summary Data Submissin Optimal Asthma Care (07/01/2012 t 06/30/2013 Dates f Service) Htline: 612-746-4522 E-mail: supprt@mncm.rg Data Prtal: https://data.mncm.rg/lgin MN Cmmunity
More informationAdvantEdge Healthcare Solutions: 2012 Physician Quality Reporting System (PQRS) Manual
AdvantEdge Healthcare Slutins: 2012 Physician Quality Reprting System (PQRS) Manual This newsletter cntains the fllwing infrmatin: 1. Eligible Prfessinals Page 1 2. PQRI Basics Page 1 3. 2011 Reprting
More informationIdentification and Management of Hypertension. Definition of HTN
1 Hypertensin (HTN) is ne f the mst cmmn diagnses in America. One in three individuals has HTN. Bth systlic and diastlic rise in bld pressure frm childhd t adulthd each are independent risk factrs fr cardivascular
More informationDo Not Cite. Draft for Work Group Review.
D Nt Cite. Draft fr Wrk Grup Review. Pst-Acute Ischemic Strke Screening and Care Measure Bundle Measure Descriptin Percentage f patients aged 18 years and lder with a diagnsis f ischemic strke r transient
More informationAPPENDIX A Certification of Advanced Disease:
APPENDIX A Certificatin f Advanced Disease: Name: DOB: Member ID: Name f Palliative Care Prgram: A. General Criteria: Check each f the fllwing that apply (All needed fr eligibility). Patient wh is likely
More informationPain Management Learning Plan
Pain Management Learning Plan Overriding Gal T imprve the quality f patient care available fr patients living with chrnic pain. Learning Outcmes By the end f the implementatin, participants will be able
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationEmergency Department Performance Measures
Emergency Department Perfrmance Measures ACEP Clinical Emergency Data Registry () ACEP Campaign Centers fr Medicare and Medicaid Services (CMS) Medicare Beneficiary Quality Imprvement Prject (MBQIP) ED
More informationNCT ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: PRIST_L_ Study Code: PRISTINAMYCIN Date: Generic drug name:
These results are supplied fr infrmatinal purpses nly. Prescribing decisins shuld be made based n the apprved package insert in the cuntry f prescriptin Spnsr/cmpany: sanfi-aventis ClinialTrials.gv Identifier:
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationo Procedures performed o Diagnoses Identified o Certain devices/equipment/supplies acquired for patient
Image Surce: https://s-media-cache-ak0.pinimg.cm/736x/7c/29/91/7c2991805f004e1ca05e42a79883f4a7.jpg 6/30/2017 Curse Objectives A Practical Guide t Cding fr Audilgists in 2017 Megan Keirans, AuD University
More informationANDREW BRAUNSTEIN. o MIT (3 degrees Computers / Management) o 25 years building Clinical Systems. o 6 Patents in Clinical Technologies
ANDREW BRAUNSTEIN MIT (3 degrees Cmputers / Management) 25 years building Clinical Systems ClinLgica Real-Time Clinical Rule Engine fr Predictive Analytics / Clinical Risk Management HealthWyse handheld
More informationIschemic heart disease (angina/chest pain)
Ischemic heart disease (angina/chest pain) External resurces Stable angina: management NICE guidelines [CG126] Updated :Aug 2016 https://www.nice.rg.uk/guidance/cg126 Chest pain f recent nset [CG95] Nvember
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationHospital Performance Series
Last Updated: March 17, 2017 Hspital Perfrmance Series Pre-perative testing befre lw-risk surgeries Technical Appendix Table f Cntents Purpse f the Technical Appendix... 1 Indicatr Technical Specificatins...
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationNational Hospital Inpatient Quality Reporting Measures Specifications Manual Release Notes
Natinal Hspital Inpatient Quality Reprting Measures Specificatins Manual Release Ntes Fr Manual Versin: 5.4 Cmpleted: Nvember 27, 2017 Guidelines fr Using Release Ntes The Release Ntes prvides mdificatins
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationMeaningful Use Roadmap Stage Edition Eligible Hospitals
Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing
More informationLyme Disease Surveillance in North Carolina
Lyme Disease Surveillance in Nrth Carlina 2008-2014 Carl Williams DVM Megan Sanza MPH Cmmunicable Disease Branch Divisin f Nrth Carlina Public Health Lyme Disease Surveillance in Nrth Carlina 2008-2014
More informationAffects a large segment of health care community Tied to health outcomes Addresses clinical conditions of high prevalence, high costs, high risks
Cding Change Applicatin Categry II CPT Cde(s) Perfrmance Measurement American Medical Assciatin, Current Prcedural Terminlgy (CPT ) Applicatin Submissin Requirements All CPT Cde Change applicatins are
More informationHeart Failure 6/29/2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018 #FSHP2018
Ht Papers & Guidelines in Cardilgy Christine Price, Pharm.D. Clinical Crdinatr PGY1 Residency Directr Disclsure I d nt have a vested interest in r affiliatin with any crprate rganizatin ffering financial
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationOral Surgery (Facial Pain) Service Specification
Oral Surgery (Facial Pain) Service Specificatin Service Cmmissiner Lead Prvider Lead Perid 2. Oral Surgery Facial Pain (SBCH Ref N. SS_046) 1. Purpse 1.1 Aims T prvide a Cnsultant-led specialist diagnstic,
More informationUNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.
Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date:
Clinical Plicy: Vedlizumab (Entyvi) Reference Number: ERX.SPA.163 Effective Date: 10.01.16 Last Review Date: 11.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationMedicare Advantage 2019 Advance Notice Part 1 21 st Century Cures Act Methodological Changes
Medicare Advantage 2019 Advance Ntice Part 1 21 st Century Cures Act Methdlgical Changes Review f Relevant Prvisins with Expert Insight January 2018 PULSE8 is privileged t bring yu a summary f key Medicare
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationHEDIS. Healthcare Effectiveness Data & Information Set (HEDIS ) QUALITY MANAGEMENT PROGRAM SECTION 8
HEDIS Healthcare Effectiveness Data & Infrmatin Set (HEDIS ) The HEDIS â audit cntains a cre set f perfrmance measures that prvide infrmatin abut custmer satisfactin, specific health care measures, and
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationCDC Influenza Division Key Points November 7, 2014
In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates
More informationQUALITY AND SAFETY MEASURES UPDATE January 2016
CLINICAL EFFECTIVENESS/SAFETY M CORE MEASURES 2015 See attached Results QUALITY AND SAFETY MEASURES UPDATE January 2016 Jint Cmmissin and CMS Cre Measure Dashbard updated with mst recent data available:
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationHOSPITAL INPATIENT & EMERGENCY DEPARTMENT ANALYTICAL SYSTEM
HOSPITAL INPATIENT & EMERGENCY DEPARTMENT ANALYTICAL SYSTEM healthdata.brhpc.rg The system prduces data reprts frm the fllwing mdules: Preventin Quality Indicatrs Acuity Stratificatin (Emergency Department)
More informationUsing Telin Mediplan to Support Patient s Medical Home
EMR TIP SHEET JANUARY 2017 Using Telin Mediplan t Supprt Patient s Medical Hme Cntents Intrductin... 3 Patient s Medical Hme... 3 Fundatin fr Success - Cmmitment t Standardizatin in the EMR... 4 Help Files...
More informationDrug Therapy Guidelines
Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,
More informationDrug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)
Drug Class Review: Lng-acting muscarinic antagnists (LAMAs) fr treatment f chrnic bstructive pulmnary disease (COPD) Cmprehensive Research Plan: Pharmacepidemilgy Unit April 10 th, 2014 ODPRN Drug Class
More information